论文部分内容阅读
PURPOSE: To evaluate selective laser trabeculoplasty (SLT)-as a replacement for medical therapy in controlled open-angle glaucoma. DESIGN: Prospective, non-random-ized, interventional clinical trial. METHODS: SLT was performed inferiorly in 66 eyes of 66 patients with medically controlled primary open-angle glaucoma (OAG) or exfoliation glaucoma, and no history of glaucoma surgery. The primary outcomewas number of medications at 6 and 12 months while maintaining a predetermined target intraocular pressure (IOP). RESULTS: The mean of the differences in medications from baseline was 2.0 (95% confidence interval=1.8-2.3) at 6 months, and 1.5 (1.27-1.73) at 12 months (P < .0001). The group mean of medications was 2.8± 1.1 at baseline, 0.7± 0.9 at 6 months, and 1.5± 0.9 at 12 months (P < .0001). Reduction in medications was attained in 64 of 66 eyes (97% ) at 6 months, and 52 f 60 (87% ) at 12 months. CONCLUSION: SLT enabled a reduction in medicine in controlled OAG over 12 months.
PURPOSE: To evaluate selective laser trabeculoplasty (SLT) -as a replacement for medical therapy in controlled open-angle glaucoma. DESIGN: Prospective, non-random-ized, interventional clinical trial. METHODS: SLT was performed inferiorly in 66 eyes of 66 patients with primary controlled primary primary open-angle glaucoma (OAG) or exfoliation glaucoma, and no history of glaucoma surgery. The primary outcome was number of medications at 6 and 12 months while maintaining a predetermined target intraocular pressure (IOP). RESULTS: The mean of the differences in medications from baseline was 2.0 (95% confidence interval = 1.8-2.3) at 6 months, and 1.5 (1.27-1.73) at 12 months (P <.0001). The group mean of medications was 2.8 ± 1.1 at baseline, 0.7 ± 0.9 at 6 months, and 1.5 ± 0.9 at 12 months (P <.0001). Reduction in medications was attained in 64 of 66 eyes (97%) at 6 months, and 52 f 60 (87%) at 12 months CONCLUSION: SLT enabled a reduction in medicine in controlled OAG over 12 months.